KLP Kapitalforvaltning AS Purchases New Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

KLP Kapitalforvaltning AS purchased a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 6,300 shares of the company’s stock, valued at approximately $2,093,000.

Other large investors have also added to or reduced their stakes in the company. State Street Corp grew its holdings in shares of Medpace by 7.2% in the third quarter. State Street Corp now owns 752,957 shares of the company’s stock valued at $251,337,000 after purchasing an additional 50,312 shares in the last quarter. Geode Capital Management LLC lifted its position in Medpace by 7.6% during the third quarter. Geode Capital Management LLC now owns 628,054 shares of the company’s stock valued at $209,885,000 after purchasing an additional 44,371 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of Medpace by 36.0% in the 3rd quarter. Wellington Management Group LLP now owns 415,255 shares of the company’s stock worth $138,612,000 after buying an additional 109,886 shares in the last quarter. American Capital Management Inc. increased its holdings in shares of Medpace by 2.6% in the 3rd quarter. American Capital Management Inc. now owns 380,646 shares of the company’s stock worth $127,060,000 after buying an additional 9,592 shares during the last quarter. Finally, GW&K Investment Management LLC raised its position in shares of Medpace by 93.9% during the 4th quarter. GW&K Investment Management LLC now owns 275,460 shares of the company’s stock valued at $91,516,000 after buying an additional 133,379 shares in the last quarter. Institutional investors own 77.98% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on the company. Robert W. Baird lifted their price target on Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research report on Monday, January 27th. Leerink Partnrs upgraded Medpace to a “hold” rating in a report on Monday. Finally, Leerink Partners started coverage on Medpace in a report on Monday. They set a “market perform” rating and a $330.00 price target on the stock. Nine equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, Medpace has an average rating of “Hold” and an average target price of $376.30.

Medpace Trading Down 0.3 %

NASDAQ:MEDP opened at $316.61 on Friday. The company has a market cap of $9.65 billion, a price-to-earnings ratio of 25.07, a price-to-earnings-growth ratio of 3.81 and a beta of 1.47. Medpace Holdings, Inc. has a twelve month low of $302.01 and a twelve month high of $459.77. The stock has a fifty day simple moving average of $336.40 and a 200-day simple moving average of $339.26.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. As a group, equities research analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.